GLP-1 Muscle Loss Prevention: The Evidence-Based Protocol

Every weight-loss intervention — diet, surgery, GLP-1 therapy — takes some lean mass along with the fat. The published number for tirzepatide in the SURMOUNT-1 DEXA substudy (Look 2025^[2]) is roughly −33.9% fat mass and −10.9% lean mass at week 72 on the 10 mg arm, with lean mass making up about a quarter of total body-weight loss. The same fraction shows up in older diet-only studies (Cava 2017^[4]) and the resistance-training meta-analyses (Sardeli 2018^[5]). The good news is that the protocol to minimize lean-mass loss has been replicated for two decades: protein at the high end of the evidence range (Krieger 2006^[6], Phillips 2016^[7]), resistance training three days per week (Sardeli 2018^[5], Longland 2016^[8]), and — for older or higher-risk patients — DEXA at baseline and again at the end of titration. This article walks through what the evidence actually says and the practical protocol it implies.

The honest summary

• Lean-mass loss is real but not catastrophic. In the SURMOUNT-1 body composition substudy (Look 2025^[2]), tirzepatide 10 mg produced −33.9% fat mass and −10.9% lean mass at week 72; the lean fraction of total weight loss was about 25%. That is the same fraction seen in dietary weight loss without medication (Cava 2017^[4]).
• Protein dose has a published threshold. Krieger 2006 (AJCN meta-regression^[6]) and Phillips 2016^[7] converge on roughly 1.6 g/kg per day as the minimum intake associated with preserved fat-free mass during energy restriction; intakes up to 2.0–2.4 g/kg add small additional benefit during intense exercise (Longland 2016^[8]).
• Resistance training is the lever. Sardeli 2018^[5] (meta-analysis of older adults in a caloric deficit) found resistance training abolished the lean-mass loss otherwise seen with diet alone. Two to three sessions per week of compound lifts is the typical protocol.
• Screen for sarcopenic obesity in older patients. The ESPEN/EASO consensus (Donini 2022^[11]) and EWGSOP2 (Cruz-Jentoft 2019^[12]) provide screening criteria; patients age ≥ 65 or with low baseline grip strength deserve a DEXA at baseline and formal sarcopenia screening before starting a GLP-1.

What the SURMOUNT-1 body composition substudy actually showed

SURMOUNT-1 (Jastreboff 2022 NEJM^[1]) randomized 2,539 adults with obesity to tirzepatide 5, 10, or 15 mg weekly or placebo for 72 weeks. Mean total body-weight loss was −15.0%, −19.5%, and −20.9% on the three active arms vs −3.1% on placebo. The pre-specified body composition substudy (Look 2025, Diabetes Obesity & Metabolism^[2]) added serial DEXA to 160 participants and reported:

• Fat mass: −33.9% from baseline at week 72 on tirzepatide 10 mg.
• Lean mass: −10.9% from baseline at week 72 on tirzepatide 10 mg.
• Lean fraction of total weight loss: about one quarter — in line with the “~25%” benchmark from diet-only weight loss.
• Fat-to-lean ratio improved overall: the ratio of fat mass to lean mass dropped substantially because the absolute fat loss was three times the absolute lean loss.

The headline interpretation: tirzepatide does not produce disproportionately more lean-mass loss than non-pharmacological weight loss of similar magnitude. It produces the same fraction of lean loss against a much larger fat loss, so the relative body composition improves.

STEP-1 and what the semaglutide picture looks like

STEP-1 (Wilding 2021 NEJM^[3]) randomized 1,961 adults to semaglutide 2.4 mg weekly or placebo and reported −14.9% total body weight at week 68. A DEXA substudy was published as part of the STEP program with a similar pattern: fat mass dropped more than lean mass, but lean mass did account for a clinically meaningful fraction of the loss. The directional message matches SURMOUNT-1: the lean fraction of weight loss with semaglutide and tirzepatide is in the same range as diet-induced weight loss, around a quarter to a third — not the 50%+ that early speculation feared.

The protein evidence: 1.6 g/kg is the floor

Three independent lines of evidence converge on the same protein dose for lean-mass preservation during a caloric deficit.

Krieger 2006^[6] meta-regressed 87 studies of energy-restricted diets and found that protein intake above ~1.05 g/kg was associated with significantly less fat-free mass loss; the dose-response continued upward. Phillips 2016^[7] reviewed the leucine-threshold and muscle protein synthesis literature and landed on roughly 1.6 g/kg per day as the practical ceiling of incremental benefit for healthy adults. Longland 2016^[8] randomized young men to either 1.2 or 2.4 g/kg during a 40% energy deficit plus high-intensity training and found the high-protein arm gained ~1.2 kg of lean mass while losing ~4.8 kg of fat — the low-protein arm preserved but did not gain. Wycherley 2012^[9] meta-analyzed 24 RCTs of higher-protein energy-restricted diets and confirmed reduced fat-free mass loss and greater fat loss vs standard-protein controls.

The practical translation for GLP-1 patients is 1.6–2.0 g/kg of current body weight per day. A 90 kg adult on Wegovy targets 144–180 g of protein daily. That target is hard to hit when a GLP-1 has cut appetite by a third, which is exactly why the protein side of the protocol fails more often than the training side.

The resistance-training evidence: two to three sessions per week

Sardeli 2018^[5] meta-analyzed six RCTs of resistance training during caloric restriction in obese older adults. Diet alone produced lean-mass loss averaging about 5% of baseline; diet plus resistance training produced effectively no lean-mass loss. The effect was robust across protocols using 2–3 sessions per week of moderate-intensity lifting. Cava 2017^[4] reviewed the broader literature and reached the same conclusion: the single most effective countermeasure to weight-loss-induced muscle loss is resistance exercise.

The training protocol that supports the published outcomes is unglamorous: compound multi-joint lifts (squat, hinge, press, row, pull), 2–3 sessions per week, progressive overload on a 3–6 rep-range working set with 1–2 backoff sets, and at least 48 hours between sessions targeting the same muscle group. The literature does not require a barbell — machine-based or dumbbell-based programs produce similar outcomes in the meta-analyses.

Creatine, vitamin D, and the supportive supplements

Creatine monohydrate 3–5 g/day is the only supplement with a position-stand-level evidence base for augmenting lean-mass preservation alongside resistance training (Kreider 2017, JISSN^[10]). The position stand reviewed several hundred studies and concluded creatine is safe, effective for resistance-training adaptation, and especially useful in older adults at sarcopenia risk — the exact population most GLP-1 patients sit inside.

Vitamin D sufficiency (serum 25-OH-D in the 30–50 ng/mL range) supports both muscle function and bone density; weight loss accelerates bone-mineral-density decline, so a baseline 25-OH-D measurement plus 1,000 mg calcium and 800–2,000 IU vitamin D daily is the usual floor. Omega-3 at 2–3 g/day has modest evidence in older adults; HMBevidence is weaker and we do not recommend it as first-line.

Magnitude: lean mass as a fraction of total weight loss

Sarcopenic obesity: who needs DEXA at baseline

The ESPEN/EASO sarcopenic obesity consensus (Donini 2022, Clinical Nutrition^[11]) and the EWGSOP2 sarcopenia consensus (Cruz-Jentoft 2019, Age and Ageing^[12]) define sarcopenia by reduced muscle strength (grip dynamometry or chair-rise time) confirmed by reduced muscle quantity (DEXA-derived appendicular lean mass index). For GLP-1 candidates, a baseline DEXA is warranted in any of:

• Age ≥ 65 — baseline sarcopenia prevalence is high.
• Grip strength below sex-specific cutoffs (< 27 kg men, < 16 kg women per EWGSOP2^[12]).
• Chair-rise time ≥ 15 seconds for 5 repetitions.
• Recent unintentional weight loss or rapid prior loss on another agent.
• Planned aggressive titration to maximum dose with target TBWL > 20%.

For lower-risk patients, bioelectrical impedance analysis (BIA) on a quarterly cadence is a reasonable substitute. BIA is less accurate at a single time point than DEXA, but within-patient change over time is informative. Clinically meaningful red flags are a > 15% drop in appendicular lean mass at any interim measurement, or a measured grip strength decline more than 10% from baseline.

The practical protocol

1. Protein target: 1.6–2.0 g/kg of current body weight per day. Anchor to the lower end if tolerating; push to 2.0 g/kg if you are on a high dose, older, or measurably losing lean mass. Use whey or casein before resistance sessions; spread across 3–4 doses of 30–40 g.
2. Resistance training: 2–3 sessions per week, compound lifts. Squat or leg press, hinge (deadlift or hip thrust), horizontal push, horizontal pull, vertical push, vertical pull. 3 working sets at 6–12 reps, progressive load.
3. Creatine monohydrate 3–5 g/day. Any time of day. No loading phase required.
4. Vitamin D + calcium. Baseline 25-OH-D; repeat at 6 months. 1,000 mg calcium and 800–2,000 IU vitamin D daily for most patients.
5. DEXA at baseline and at end of titration (~week 36) for any patient meeting the sarcopenic-obesity screening criteria above. Quarterly BIA for everyone else.
6. Re-evaluate at 6 months. If appendicular lean mass index has dropped > 15% or grip strength has fallen > 10%, increase protein, add a third resistance session, and consider slowing the dose ladder.

Related research and tools

• Exercise pairing on a GLP-1 — the resistance-training half of the protocol in depth
• Best protein powders for GLP-1 weight loss — whey vs casein vs plant blends, leucine content per serving
• Creatine on a GLP-1 — the Kreider position stand and what 3–5 g/day actually does
• Tirzepatide and lean mass — the SURMOUNT-1 body composition substudy in detail
• Ozempic muscle loss — semaglutide-specific protection strategies
• What to eat on a GLP-1 — how to hit 1.6 g/kg when appetite is cut by a third
• GLP-1 protein calculator — calculate your daily target by current weight
• GLP-1 exercise pairing configurator — build a 2–3 session weekly template

Important disclaimer. This article is educational and does not constitute medical advice. Resistance training protocols should be individualized and, for patients with cardiovascular disease, prior injury, or significant deconditioning, supervised by a qualified clinician or certified strength coach. Protein-intake recommendations assume normal renal function; patients with chronic kidney disease should discuss protein targets with their nephrologist. DEXA exposure is low but non-zero; order-of-operations and frequency should be coordinated with the prescribing clinician. PMIDs were verified live against the PubMed E-utilities API on 2026-05-28.

Last verified: 2026-05-28. Next review: every 12 months, or sooner if new prospective trial data on GLP-1 body composition (STEP-derived or SURMOUNT-derived substudies) is published.